CN1353575A - 用树状细胞一肿瘤细胞或树状细胞一病毒细胞衍生的免疫原在体外诱导抗原特异性t－销细胞 - Google Patents

用树状细胞一肿瘤细胞或树状细胞一病毒细胞衍生的免疫原在体外诱导抗原特异性t－销细胞 Download PDF

Info

Publication number
CN1353575A
CN1353575A CN00808298A CN00808298A CN1353575A CN 1353575 A CN1353575 A CN 1353575A CN 00808298 A CN00808298 A CN 00808298A CN 00808298 A CN00808298 A CN 00808298A CN 1353575 A CN1353575 A CN 1353575A
Authority
CN
China
Prior art keywords
cell
cells
dendritic
described method
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN00808298A
Other languages
English (en)
Chinese (zh)
Inventor
小L·D·法罗
W·斯托尔库斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of CN1353575A publication Critical patent/CN1353575A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN00808298A 1999-03-31 2000-03-30 用树状细胞一肿瘤细胞或树状细胞一病毒细胞衍生的免疫原在体外诱导抗原特异性t－销细胞 Pending CN1353575A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28267999A 1999-03-31 1999-03-31
US09/282,679 1999-03-31

Publications (1)

Publication Number Publication Date
CN1353575A true CN1353575A (zh) 2002-06-12

Family

ID=23082644

Family Applications (1)

Application Number Title Priority Date Filing Date
CN00808298A Pending CN1353575A (zh) 1999-03-31 2000-03-30 用树状细胞一肿瘤细胞或树状细胞一病毒细胞衍生的免疫原在体外诱导抗原特异性t－销细胞

Country Status (6)

Country Link
EP (1) EP1168924A4 (https=)
JP (1) JP2002539805A (https=)
CN (1) CN1353575A (https=)
AU (1) AU4183100A (https=)
CA (1) CA2367590A1 (https=)
WO (1) WO2000057705A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102827826A (zh) * 2012-09-11 2012-12-19 赵永祥 一种诱导树突状细胞与肿瘤细胞融合的方法
CN103109191A (zh) * 2010-09-17 2013-05-15 洛菲厄斯生物科学有限责任公司 利用逆转录定量实时PCR(RT-qPCR)技术检测、区分和定量T细胞群体的方法
CN105532575A (zh) * 2016-01-14 2016-05-04 中国科学院昆明动物研究所 一种单纯疱疹病毒感染树鼩动物模型的构建、评估方法及其应用
WO2016145578A1 (en) * 2015-03-13 2016-09-22 Syz Cell Therapy Co. Methods of cancer treatment using activated t cells
US11248208B2 (en) 2018-03-30 2022-02-15 Syz Cell Therapy Co. Multiple antigen specific cell therapy methods

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050169898A1 (en) 1997-04-15 2005-08-04 Jianlin Gong Cell fusions and methods of making and using the same
DE69839215T2 (de) 1997-04-15 2009-03-19 Dana-Farber Cancer Institute, Inc., Boston Dendritische zellhybride
EP1226235A2 (de) * 1999-10-22 2002-07-31 LESKOVAR, Peter Zellkonstrukte, die für die immuntherapie geeignet sind, deren herstellung und verwendung
JP5054875B2 (ja) * 2000-02-11 2012-10-24 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 樹状細胞ハイブリッドによって活性化される細胞傷害性ｔリンパ球
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
DE10164819A1 (de) * 2001-11-20 2005-05-19 Deml, Ludwig, Dr. Verfahren zur Identifizierung von Zielepitopen der T-Zell-vermittelten Immunantwort und zum Nachweis Epitop-spezifischer T-Zellen
EP2054444B1 (en) 2006-08-04 2016-11-02 MedImmune Limited Antibodies to erbb2
EP2606897A1 (en) 2011-12-22 2013-06-26 Laboratorios Del. Dr. Esteve, S.A. Methods and compositions for the treatment of diseases caused by enveloped viruses
CN104830793A (zh) * 2015-05-05 2015-08-12 杨光华 基于lmp-1抗原的dc细胞、靶向性免疫细胞群及其制备方法和用途
CN108076642A (zh) 2015-05-08 2018-05-25 威尔逊沃夫制造公司 改进的用于测试的培养方法和装置
CN107921063A (zh) 2015-07-02 2018-04-17 普莱瓦克斯免疫肿瘤学公司 用于采用登革病毒与树突细胞的联合疗法的组合物及方法
CN108291205A (zh) 2015-09-26 2018-07-17 普莱瓦克斯免疫肿瘤学公司 用于产生树突细胞的组合物和方法
JP2020500847A (ja) 2016-11-16 2020-01-16 プライムヴァックス イミュノ−オンコロジー，インク． 癌の処置のための併用免疫療法
EP3565567A4 (en) 2017-01-04 2020-07-29 Primevax Immuno-Oncology, Inc. COMPOSITIONS AND METHODS OF THERAPY WITH DENGUE VIRUS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69634750T2 (de) * 1995-03-31 2006-02-23 Université Libre de Bruxelles DENDRITENZELLEN/TUMORZELLEN Hybirde ZUR INDUKTION EINER ANTI-TUMOR ANTWORT
DE69839215T2 (de) * 1997-04-15 2009-03-19 Dana-Farber Cancer Institute, Inc., Boston Dendritische zellhybride
WO1999037313A1 (en) * 1998-01-26 1999-07-29 Genzyme Corporation Immune effector cell hybrids

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103109191A (zh) * 2010-09-17 2013-05-15 洛菲厄斯生物科学有限责任公司 利用逆转录定量实时PCR(RT-qPCR)技术检测、区分和定量T细胞群体的方法
CN103109191B (zh) * 2010-09-17 2016-04-13 洛菲厄斯生物科学有限责任公司 利用逆转录定量实时PCR(RT-qPCR)技术检测、区分和定量T细胞群体的方法
CN102827826A (zh) * 2012-09-11 2012-12-19 赵永祥 一种诱导树突状细胞与肿瘤细胞融合的方法
WO2016145578A1 (en) * 2015-03-13 2016-09-22 Syz Cell Therapy Co. Methods of cancer treatment using activated t cells
CN107735492A (zh) * 2015-03-13 2018-02-23 深圳源正细胞医疗技术有限公司 使用活化t细胞治疗癌的方法
US10967054B2 (en) 2015-03-13 2021-04-06 Syz Cell Therapy Co. Methods of cancer treatment using activated T cells
US11219675B2 (en) 2015-03-13 2022-01-11 Syz Cell Therapy Co. Methods of cancer treatment using activated T cells
US11229689B2 (en) 2015-03-13 2022-01-25 Syz Cell Therapy Co. Methods of cancer treatment using activated T cells
US12312597B2 (en) 2015-03-13 2025-05-27 HRY Z (Shanghai) Biotech Co. Methods of cancer treatment using activated t cells
CN105532575A (zh) * 2016-01-14 2016-05-04 中国科学院昆明动物研究所 一种单纯疱疹病毒感染树鼩动物模型的构建、评估方法及其应用
US11248208B2 (en) 2018-03-30 2022-02-15 Syz Cell Therapy Co. Multiple antigen specific cell therapy methods

Also Published As

Publication number Publication date
WO2000057705A1 (en) 2000-10-05
EP1168924A4 (en) 2002-09-04
EP1168924A1 (en) 2002-01-09
JP2002539805A (ja) 2002-11-26
CA2367590A1 (en) 2000-10-05
AU4183100A (en) 2000-10-16

Similar Documents

Publication Publication Date Title
Timmerman, MD et al. Dendritic cell vaccines for cancer immunotherapy
Ashley et al. Bone marrow–generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors
Dhodapkar et al. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells
AU2003302504B2 (en) Rapid one-step method for generation of antigen loaded dendritic cell vaccine from precursors
CN1353575A (zh) 用树状细胞一肿瘤细胞或树状细胞一病毒细胞衍生的免疫原在体外诱导抗原特异性t－销细胞
EP1012240B1 (en) Cancer immunotherapy with semi-allogeneic cells
Jeras et al. In vitro preparation and functional assessment of human monocyte-derived dendritic cells—potential antigen-specific modulators of in vivo immune responses
US9694059B2 (en) Ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases
US20140141046A1 (en) Method and composition for producing a cellular allogeneic vaccine
Dhodapkar et al. Active immunization of humans with dendritic cells
Tsang et al. The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells
US20180085398A1 (en) Compositions and methods of treating cancer
WO2020145222A1 (ja) 新規ネオアンチゲン及びそれらを用いたがん免疫治療薬
AU2016243626A1 (en) Compositions and methods of treating multiple myeloma
US20190125848A1 (en) Dendritic cell-extracellular vesicle fusions and methods of using same
Engleman Dendritic cells: potential role in cancer therapy
US20050170503A1 (en) In vitro induction of antigen-specific T-cells using dendritic cell-tumor cell or dendritic cell-viral cell derived immunogens
Yamasaki et al. Presentation of synthetic peptide antigen encoded by the MAGE-1 gene by granulocyte/macrophage-colony-stimulating-factor-cultured macrophages from HLA-A1 melanoma patients
Peshwa et al. Generation of primary peptide-specific CD8+ cytotoxic T-lymphocytes in vitro using allogeneic dendritic cells
Ponsaerts Dendritic cell vaccines for immunity and tolerance: mRNA electroporation as a tool for efficient gene transfer
AU2007202210A1 (en) Rapid one-step method for generation of antigen loaded dendritic cell vaccine from precursors
SE523515C2 (sv) Ny metod och komposition för framställning av ett cellulärt allogent vaccin

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication